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Summary box
What is already known?
 ► Antibiotic use has been increasing globally in recent 
years.
 ► Several studies have shown that children are im-
portant users of antibiotics in many settings but 
childhood antibiotic consumption has not been 
quantified globally.
What are the new findings?
 ► Based on global antibiotic sales data, consumption 
of antibiotics overall and in specific child-appropri-
ate formulations remained relatively constant be-
tween 2011 and 2015 in both high-income and low/
middle-income countries.
 ► Trends in specific antibiotics differed, with an in-
crease in the use of amoxicillin in combination with 
clavulanic acid in low/middle-income countries.
What do the new findings imply?
 ► There appears to have been limited progress in re-
ducing antibiotic prescribing in high-income coun-
tries and increasing access to antibiotics in low/
middle-income countries.
AbSTrACT
Introduction Understanding patterns of antibiotic 
consumption is essential to ensure access to appropriate 
antibiotics when needed and to minimise overuse, which 
can lead to antibiotic resistance. We aimed to describe 
changes in global antibiotic consumption between 2011 
and 2015.
Methods We analysed wholesale data on total antibiotic 
sales and antibiotics sold as child-appropriate formulations 
(CAFs), stratified by country income level (low/middle-
income and high-income countries (LMICs and HICs)). 
The volume of antibiotics sold per year was recorded 
for 36 LMICs and 39 HICs, measured in standard units 
(SU: 1 SU is equivalent to a single tablet, capsule or 5 
mL ampoule/vial/oral suspension) and SU per person, 
overall and as CAFs. Changes over time were quantified 
as percentage changes and compound annual growth 
rates in consumption per person. Analyses were conducted 
separately for total sales, sales of antibiotics in the Access 
and Watch groups of the WHO’s Essential Medicines List 
for children 2017, for amoxicillin and amoxicillin with 
clavulanic acid.
results Antibiotic consumption increased slightly 
between 2011 and 2015, from 6.85×1010 SU to 7.44×1010 
SU overall and from 1.66×1010 SU to 1.78×1010 SU for 
CAFs. However, trends differed between countries and 
for specific antibiotics; for example, consumption of 
amoxicillin as CAFs changed little in LMICs and HICs, but 
that of amoxicillin with clavulanic acid increased by 6.8% 
per year in LMICs and decreased by 1.0% per year in HICs.
Conclusions As measured in standard units in sales 
data, the rate of increase in global antibiotic consumption 
may be slowing. However, the trends appear to differ 
between countries and drugs. In the absence of routine 
surveillance of antibiotic use in many countries, these 
data provide important indicators of trends in consumption 
which should be confirmed in national and local studies of 
prescribing.
InTroduCTIon
Improving and maintaining access to anti-
biotics presents unique challenges, with the 
need to ensure availability of appropriate 
treatment balanced against limiting inap-
propriate use and emergence of resistance. 
The WHO has recommended that countries 
implement surveillance of antimicrobial 
consumption,1 but this may be challenging, 
particularly in low-income and middle-in-
come settings in which robust surveillance 
systems are generally not available.
In the absence of global surveillance data, 
information on international antibiotic sales 
can provide a proxy measure of consump-
tion.2–4 Based on such data, global consump-
tion of antibiotics, including last resort 
treatments such as polymyxins, increased 
between 2000 and 2010, particularly in 
low-income and middle-income coun-
tries.2 4 This increase appeared to continue 
into 2015, particularly, but not exclusively, in 
low-income and middle-income countries,3 
where increasing consumption potentially 
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reflects improvements in access rather than necessarily 
overuse.
One limitation of using sales data to estimate consump-
tion is the lack of information on the individuals to 
whom the drugs were prescribed, including patient age. 
However, information on the antibiotic formulation 
may be available and could provide a proxy identifier of 
drugs dispensed to children, as some oral formulations 
are particularly suitable for children.5 Quantifying global 
paediatric antibiotic use is important as childhood expo-
sure to antibiotics in many settings is high; for example, 
in New Zealand, 97% of children had received at least 
one course of antibiotics by the age of 5 years.6 Children 
in low-income settings are also commonly exposed to 
antibiotics, with an average consumption of 4.9 courses 
per child-year reported among children aged <2 years 
in eight low-income settings (Bangladesh, Brazil, India, 
Nepal, Pakistan, Peru, South Africa and Tanzania), 
although frequency and patterns of use varied substan-
tially between sites.7 Paediatric antimicrobial stewardship 
programmes may therefore play a critical role in reducing 
the emergence of bacterial resistance. However, previous 
studies of antibiotic use have often either not focused on 
children8–16 or have used cross-sectional designs,17 often 
in hospitals.18–21 A few studies have reported on trends 
in paediatric antibiotic use, in individual countries or 
regions or a small number of countries,22–25 using data 
on health insurance claims,22 pharmacy databases,23 
community surveys24 and electronic health records.25
In this paper, we aim to describe global trends in anti-
biotic consumption using wholesale data, stratified by 
country income level, overall and for specific ‘child-ap-
propriate formulations’ (CAFs) as a proxy for consump-
tion by children.
MeTHodS
Data on antibiotic (Anatomic Therapeutic Chemical 
(ATC) code J01) sales during 2011–2015 were obtained 
from the IQVIA MIDAS database. The database contains 
annual figures summarising pharmacy sales of specific 
antibiotic drugs and combinations in 75 countries/
regions (Guatemala, El Salvador, Honduras, Nicaragua, 
Costa Rica and Panama are aggregated as Central 
America, and Benin, Burkina Faso, Cameroon, Côte 
d'Ivoire, Democratic Republic of the Congo, Gabon, 
Guinea, Mali, Senegal and Togo as Francophone West 
Africa); online supplementary appendix table 1 summa-
rises the sectors covered in each included country. Anti-
biotic consumption is expressed in standard units (SU), 
with 1SU defined by IQVIA as a single tablet, capsule or 
ampoule/vial or 5 mL oral suspension. Countries were 
classified based on income using World Bank catego-
ries.26 Low-income, lower middle and upper middle 
income countries were considered together as low/
middle-income (LMICs). The remaining countries were 
classified as high income (HICs).
The dataset does not include information on the recip-
ients of prescriptions. To estimate antibiotic consump-
tion by children, all recorded formulations were 
classified by two senior paediatric specialist pharmacists 
into those considered to be ‘child-appropriate’ formu-
lations (CAFs, that is, formulations available as syrups/
liquids or dispersible tablets/solids that become liquid 
on intake or swallowing) and others (online supple-
mentary appendix). Analyses are presented overall (all 
formulations combined) and for the subset of formula-
tions considered to be CAFs.
Antibiotics were also grouped into Access, Watch and 
Reserve (AWaRe) groups based on the classification used 
in the WHO’s 2017 revision of the Essential Medicines 
List for children (EMLc).27 Access antibiotics are first-
choice or second-choice treatments for major clinical 
syndromes (eg, amoxicillin for pneumonia) and should 
be routinely accessible for appropriate use. Antibiotics 
in the Watch category are first-choice or second-choice 
treatments for specific indications but carry a higher 
risk of resistance emerging, while Reserve antibiotics are 
considered drugs of last resort. Antibiotics not repre-
sented in the EMLc were grouped as ‘Unclassified’; this 
group includes monotherapies not included on the list 
(eg, second generation cephalosporins) and combina-
tion treatments not included on the EMLc (irrespective 
of whether any of the constituents of the combination are 
on the EMLc). The nine antibiotics which appear in the 
Access group only for specific clinical conditions and are 
otherwise classified in the Watch group were considered 
as Watch.
Annual antibiotic consumption per capita was calcu-
lated overall and for CAFs, using UN estimates of the 
total and 0–4-year-old population for each country repre-
sented in IQVIA,28 assuming that CAFs are prescribed 
for children aged <5 years. We first described trends 
in consumption of antibiotics globally over the period 
2011–2015, measured in SU and in SU/person (or per 
child). Changes in overall consumption were assessed 
globally and for individual countries as the percentage 
change in consumption per person (or per child aged 
<5 years), calculated as 100 × (SU per person in 2015 – 
SU per person in 2011)/SU per person in 2011). A posi-
tive percentage change therefore represents an increase 
in consumption. Similar to van Boeckel et al,4 we also 
calculated the compound annual growth rate (CAGR) in 
consumption per person and per child:
 
CAGR = 100 ×
[(
Consumption per person in 2015
Consumption per person in 2011
) 1
N − 1
]
 
where N is the number of years of data available. For 
CAFs, calculation of the CAGR was analogous but 
used consumption per child aged 0–4 years in place of 
consumption per person. We repeated these analyses for 
Access and Watch antibiotics and separately for amoxi-
cillin and amoxicillin with clavulanic acid.
Analyses were conducted using Stata V.15.
 o
n
 8 M
arch 2019 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2018-001241 on 27 February 2019. Downloaded from 
Jackson C, et al. BMJ Glob Health 2019;4:e001241. doi:10.1136/bmjgh-2018-001241 3
BMJ Global Health
Figure 1 Global antibiotic consumption, all formulations and child-appropriate formulations in low/middle-income and high-
income countries, 2011–2015. Consumption is measured in SU and in SU/person (all formulations) or SU/child aged 0–4 years 
(child-appropriate formulations). Source: IQVIA. Note the differing Y axis scales.
ethics statement
All data were supplied aggregated at country level with no 
individual-level information. Therefore, ethical approval 
for this analysis was not required.
Patient and public involvement
There was no patient or public involvement in study 
design, analysis or reporting.
reSulTS
Global consumption of antibiotics, 2011–2015
In total, 75 countries/regions contributed data to IQVIA 
for the period 2011–2015 (36 low/middle-income 
settings and 39 high-income settings). Overall, antibi-
otic consumption increased from 6.85×1010 SU in 2011 
to 7.44×1010 SU in 2015, an increase of 8.6%. Consump-
tion of CAFs increased by 7.3%, from 1.66×1010 SU to 
1.78×1010 SU. These estimates correspond to CAGRs 
in consumption per person of 0.9% per year in overall 
consumption per person and 1.2% per year in consump-
tion per child of CAFs. Combining LMICs and HICs, the 
four antibiotics with the highest reported sales of CAFs 
in 2015 were amoxicillin (4.21×109 SU), amoxicillin with 
clavulanic acid (3.55×109 SU), cefixime (1.86×109 SU) 
and sulfamethoxazole with trimethoprim (0.88×109 SU).
The volume of antibiotics consumed (measured in 
SU) was higher in LMICs than HICs, both overall and 
for CAFs (partially reflecting the higher population in 
LMICs); however, consumption per person was higher 
in HICs (figure 1). The increase in consumption seen 
in LMICs between 2011 and 2012 was mostly due to 
an increase reported from China. From 2012 to 2015, 
reported consumption of antibiotics changed relatively 
little in LMICs contributing to IQVIA (from 32.0 SU/
child to 32.2 SU/child for CAFs and from 9.9 SU/person 
to 10.8 SU/person in total). For HICs, there were slight 
reductions in volume of consumption between 2011 and 
2015: 6.7% in consumption/child of CAFs and 4.8% in 
consumption/person overall (figure 1). These estimates 
for HICs correspond to CAGRs of −1.4% per year for 
CAFs and −1.0% per year overall.
The patterns of change in consumption per person, 
as measured by the CAGR, differed markedly between 
countries in both LMICs and HICs, although the range of 
changes was greater in the former (figure 2). The median 
CAGR in CAF consumption per child was a reduction of 
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Figure 2 Compound annual growth rate in consumption per person (all formulations) and per child aged 0–4 years (child-
appropriate formulations) of antibiotics, 2011–2015, for individual countries, by country income. Source: IQVIA.
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Figure 3 Consumption per person (all formulations) and per child aged 0–4 years (child-appropriate formulations) of 
antibiotics in Access, Watch, Reserve and Unclassified categories, 2011–2015, in low/middle-income and high-income 
settings. Source: IQVIA.
0.18% per year (IQR 2.4% decrease to 2.1% increase per 
year) in LMICs and a reduction of 1.8% per year (IQR 
2.7% decrease to 0.7% increase per year) in HICs. For 
all formulations, the median CAGR in consumption 
per person was a 0.37% decrease per year (IQR 2.4% 
decrease to 1.5% increase per year) in LMICs and a 1.1% 
decrease per year (IQR 1.8% decrease to 0.4% increase 
per year) in HICs.
Antibiotic use in relation to WHo stewardship categories
The highest levels of consumption per person and per 
child were reported for Access antibiotics overall and 
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Table 1 Compound annual growth rates in consumption of Access and Watch antibiotics, overall and in child-appropriate 
formulations, 2011–2015 (source: IQVIA)
Antibiotic stewardship 
category 
CAGR, all formulations
(% per year, median (IQR))
CAGR, CAFs
(% per year, median (IQR))
LMICs HICs LMICs HICs
Access −0.4 (−3.1 to 1.6) −0.6 (−1.9 to 1.1) −0.5 (−2.9 to 2.4) −0.7 (−2.3 to 1.2)
Watch 0.5 (−0.5 to 2.6) −1.6 (−3.5 to 0.6) 1.6 (−1.0 to 4.7) −2.8 (−8.6 to −0.5)
CAFs, child-appropriate formulations; CAGR, compound annual growth rate; HICs, high-income countries; LMICs, low/middle-income 
countries.
Figure 4 Consumption of amoxicillin and amoxicillin with clavulanic acid, per child aged 0–4 years, 2011–2015. Source: 
IQVIA.
for CAFs (figure 3). For CAFs, consumption per child of 
Watch and Unclassified antibiotics was similar between 
LMICs and HICs, although Access use was considerably 
higher in the latter. Consumption of Reserve drugs was 
very low in both income settings.
There was little change in the consumption of Access 
and Watch drugs over time (table 1), with the largest 
magnitude CAGR being a median 2.8% per year decrease 
in consumption of Watch antibiotics in CAFs in HICs. 
Again, there were substantial variations between countries, 
particularly for Watch antibiotics for which increases in 
consumption were generally greater in LMICs compared 
to HICs (online supplementary appendix figure 1).
Changes in use of amoxicillin and amoxicillin with clavulanic 
acid
In HICs, consumption of CAFs of amoxicillin and amox-
icillin with clavulanic acid changed relatively little over 
the period 2011–2015 (figure 4), with CAGRs of 0.5% 
per year and −1.0% per year, respectively. In LMICs, the 
CAGR for amoxicillin was again relatively small (0.14% 
per year). However, usage per child of CAFs of amoxi-
cillin with clavulanic acid increased at a rate of 6.8% per 
year, with usage almost equalling that of CAFs of amoxi-
cillin alone in 2015.
Again, these global trends obscured marked variation 
at country level in both HICs and LMICs (online supple-
mentary appendix figure 2). Increases in use were more 
likely in LMICs than HICs, particularly for amoxicillin 
with clavulanic acid.
dISCuSSIon
We present the first international analysis of temporal 
changes in antibiotic consumption according to formu-
lation type. Global antibiotic consumption (both overall 
and of CAFs), as measured in standard units by IQVIA 
sales data, changed relatively little between 2011 and 
2015. However, there were marked differences between 
countries in trends over time, with some countries 
showing substantial increases in antibiotic use, and trends 
differed by antibiotic. Global use of last-resort (Reserve) 
drugs was low. Consumption per child of antibiotics in 
CAFs was higher than consumption per capita overall, 
consistent with the expected high consumption among 
young children.18 29
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The IQVIA dataset is unique in providing extensive, 
long-term information from a large number of countries, 
and the reported data are internally validated against 
alternative sources of sales data.30 However, there are 
several limitations in using this dataset to estimate trends 
in antibiotic consumption. The data are not intended 
to necessarily reflect countries’ full national sales, but 
only the sectors or distribution channels from which 
data are collected. For example, in LMICs, no hospital 
data are collected in 17 countries, and in some of these 
only the purchases made from commercial wholesalers 
are included (see online supplementary appendix table 
1 for further information). Coverage in LMICs also 
refers mainly to community antibiotic use whereas HICs 
also include hospital data. Consequently, it is difficult 
to define the population covered in each country; we 
used national population denominators but these may 
overestimate the population covered, particularly in 
LMICs, leading us to underestimate antibiotic sales per 
person (and per child). Variations in representativeness 
and coverage between countries and over time make it 
difficult to assess the comparability of data between indi-
vidual countries; for this reason, we have not presented 
data for named countries but instead highlight apparent 
variation.
Furthermore, many low-income countries, where the 
infection burden and therefore need for antibiotics are 
greatest (and where access to, and rational prescribing 
of, antibiotics may be particularly difficult),31 are not 
represented in the dataset (only seven low-income coun-
tries, all within the aggregated region of Francophone 
West Africa, contributed to IQVIA over the study period). 
Finally, sales data do not necessarily reflect consumption; 
the extent to which they do may vary between settings 
(eg, due to differences in healthcare systems and the 
volume of imports and exports). Despite these important 
biases, the overall direction of which is difficult to ascer-
tain, the dataset provides a useful indication of global 
trends in antibiotic use. Thus, while there is potential for 
error in our quantitative estimates, our key conclusions 
are likely to be valid and highlight the need for coun-
tries to examine local consumption data in the context of 
their national epidemiology, resistance patterns and data 
collection systems.
Understanding to whom antibiotics are prescribed can 
assist with planning stewardship activities. Unfortunately, 
sales data do not easily lend themselves to analysis of 
consumption by specific groups, for example, by age. We 
therefore used the type of formulation as a proxy for age, 
assuming that the defined CAFs would be prescribed to 
children aged <5 years (and using corresponding popula-
tion denominators). The classification of CAFs was devel-
oped by two senior paediatric research pharmacists but is 
somewhat subjective. CAFs may be used by older children 
and by adults, particularly those with swallowing difficul-
ties due to advanced age or comorbidities. Consequently, 
we may have overestimated antibiotic consumption 
by young children, particularly in HICs where elderly 
individuals and those with comorbidities comprise a 
larger percentage of the population. The extent of this 
error might increase over time, although over the rela-
tively short study period any such change is likely to be 
minor. These factors could disguise any true reduction 
in childhood antibiotic consumption over time. Despite 
this, we saw a slight reduction in consumption of CAFs 
in HICs and little change in LMICs. Conversely, formu-
lations which could be given to both adults and children 
(eg, intravenous) were not considered child-appropriate, 
which would underestimate total antibiotic consumption 
by children. For example, cefazolin and amikacin (which 
appear on the EMLc as powder and solution for injection, 
respectively and are classified as Access drugs)27 are not 
available as CAFs; and solid formulations of drugs other 
than antibiotics may be used by young children when 
paediatric formulations are not available.32 In addition, 
off-label use of formulations not approved for use in chil-
dren would not be accounted for in our analysis of CAFs. 
Our defined CAFs are likely to be mainly consumed in 
the community, where the majority of antibiotic use 
occurs;33 these data must therefore be considered along-
side hospital data to obtain a fuller picture of antibiotic 
consumption.
Apparent changes in antibiotic consumption may be 
(at least partially) artefacts of changes in reporting prac-
tices or drug availability. Any real increases in consump-
tion of antibiotics may reflect improved access to 
appropriate treatments or increasing inappropriate use. 
We cannot distinguish between these factors, as the data 
did not include information on indications for prescrip-
tions or microbiological data. Furthermore, an increase 
in consumption of antibiotics in CAFs may represent a 
shift to using these formulations in preference to others. 
Without patient-level data on clinical indication and caus-
ative organism (including antibiotic resistance profiles), 
we cannot assess the appropriateness of prescribing. 
Assessing the suitability of CAFs is also beyond the scope 
of this paper (eg, parents may have difficulty reconsti-
tuting powders,34 and liquid formulations may require 
refrigeration35).
Existing data on trends in antibiotic consumption at 
a global level, especially in the community, are fairly 
limited. Considering all age groups, a previous analysis 
of IQVIA data 2000–2010 reported a dramatic increase 
in consumption globally, particularly in the BRICS coun-
tries (Brazil, Russia, India, China and South Africa), 
but trends varied between countries. A recent analysis 
reported that this increase continued up to 2015, with 
consumption measured in defined daily doses (DDDs) 
and that patterns of change varied by country and anti-
biotic.3 This contrasts with the plateau in consumption 
measured in SUs which we report. This is most likely 
accounted for by the different units used. We opted not 
to convert SUs (as available in the dataset) to DDDs, 
as DDDs do not account for the age-based or weight-
based dosing used in treating children of different ages 
and sizes. DDDs could also be influenced by changes 
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in dosage. However, the differences which we highlight 
between high-income and lower-income countries are 
consistent with the previous analysis,3 and we add infor-
mation on the AWaRe categories and two specific highly 
used drugs, amoxicillin and amoxicillin with clavulanic 
acid. Our results are also consistent with broader litera-
ture showing different trends in antibiotic consumption, 
measured from a variety of data sources, over time in 
different settings. For example, electronic primary care 
data from five European countries showed no evidence 
of a trend in the prevalence of antibiotic prescribing 
between 2004 and 2009,16 whereas numbers of antibi-
otic prescriptions and sales increased by 25% and 57%, 
respectively, between 2008 and 2011 in Namibia.36
Data on trends in antibiotic use by children are also 
limited but again suggest variation according to both 
country and antibiotic.22–25 Our analyses provide results 
from a single dataset for 75 countries/regions, aiding 
understanding of overall patterns of antibiotic usage 
to complement previous national and regional anal-
yses and highlighting differences between high-income 
and low/middle-income settings, in overall trends and 
in use of specific antibiotics. Ecological studies such as 
these provide valuable indications of potential areas for 
improvements in antibiotic prescribing, but longitudinal, 
individual-level cohort studies are also needed to give 
insight into individual-level patterns, determinants and 
indications for antibiotic use.6 7
While preferences for different types of antibiotics 
vary between settings,16 37–39 amoxicillin, with or without 
clavulanic acid, is frequently reported to be one of 
the most commonly used, particularly in community 
prescribing.6 36–38 40 41 Although recommended as a 
first-choice treatment only for specific indications,27 
CAFs of amoxicillin with clavulanic acid were sold in 
volumes similar to those of amoxicillin alone in LMICs. 
The reasons for this increase, which was not driven by 
any particular country, are unclear, but could relate to 
real or perceived increases in resistance to amoxicillin 
or increases in dosage or duration of treatment. The 
increase in sales of amoxicillin with clavulanic acid may 
mean that children receive more expensive treatment 
(depending on the precise formulation),42 with little 
additional clinical benefit.
Antibiotics which appear on the EMLc are catego-
rised into the Access, Watch and Reserve groups to 
assist with stewardship.27 However, antibiotics not on 
the EMLc (the ‘Unclassified’ category) account for a 
substantial percentage of antibiotic consumption in the 
IQVIA dataset. This is a heterogeneous group of drugs 
and combinations. Some of these are widely used treat-
ments which are generally considered safe and effec-
tive and may be appropriate treatments, but do not 
meet the current criteria for being on the EMLc, for 
example, second generation cephalosporins and several 
narrow-spectrum or beta-lactamase resistant penicillins. 
Others are variations on combinations which appear on 
the EMLc, for example, amoxicillin with beta lactamase 
inhibitors other than clavulanic acid. Still others are drug 
combinations, some, all or none of the constituents of 
which may be on the EMLc. We have not analysed the 
composition of these combinations. Previous analysis has 
found a high proportion of Watch and Reserve consump-
tion in India to be accounted for by fixed dose combina-
tions (FDCs).43 Based on IQVIA data from eight Latin 
American countries (1999–2009), 70% of FDCs were 
considered to lack evidence in support of combined use 
and a further 21% were considered potentially unsafe, 
with 20% of consumption in 2009 being FDCs.44 These 
studies highlight the need to analyse these combinations 
in detail and to consider their implications for steward-
ship programmes.
ConCluSIon
Global antibiotic consumption, as measured in standard 
units and recorded in IQVIA sales data, changed relatively 
little between 2011 and 2015. However, the direction and 
magnitude of change differed between countries and 
drugs, for both total consumption and consumption of 
CAFs, although these comparisons are subject to several 
caveats. The relative importance of improvements in 
access to appropriate treatments versus changes in inap-
propriate usage remains to be determined.
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